A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Essential Tremor

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Essential Tremor

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs CX 8998 (Primary)
  • Indications Arrhythmias; Essential tremor
  • Focus Proof of concept; Therapeutic Use
  • Acronyms T-CALM Sudy
  • Sponsors Cavion
  • Most Recent Events

    • 05 Oct 2018 Status changed from recruiting to completed.
    • 05 Oct 2018 According to a Cavion media release, data from this study will be preasented at the International Congress of Parkinsons Disease and Movement Disorders.
    • 05 Oct 2018 Results published in the Cavion Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top